Light‐chain amyloid myopathy isolated to skeletal muscles: A case report
Clinical Case Reports, 2020 Isolated amyloidosis, especially of amyloid light‐chain type, is an infrequent disease. Systemic chemotherapy for light‐chain amyloidosis isolated to skeletal muscles plays a key role to reduce clonal plasma cells producing aberrant immunoglobulin.
Toshihiro Matsukawa +5 more
doaj +1 more source
99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis
European Heart Journal-Cardiovascular Imaging, 2021 Aims Technetium-99m-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD scintigraphy) is recognized as highly accurate for the non-invasive diagnosis of transthyretin (ATTR) cardiac amyloidosis (CA).
C. Quarta +15 more
semanticscholar +1 more source
Three-dimensional structure of an immunoglobulin light-chain dimer with amyloidogenic properties [PDF]
, 2002 The X-ray structure of an immunoglobulin light-chain dimer isolated from the urine as a 'Bence-Jones protein' from a patient with multiple myeloma and amyloidosis (Sea) was determined at 1.94 Angstrom resolution and refined to R and R-free factors of 0 ...
Bourne, P. C. +10 more
core +2 more sources
AMYLOID GOITER AS THE FIRST RECOGNIZABLE MANIFESTATION OF IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS. [PDF]
AACE Clin Case Rep, 2019 Orrego JJ, Chorny JA.
europepmc +2 more sources
Monoclonal gammopathy of renal significance: Diagnostic workup [PDF]
, 2017 The clinical spectrum of diseases associated with monoclonal gammopathies is wide and they are most commonly the consequence of renal deposition of monoclonal immunoglobulin or its components.
Cabrita, A. +5 more
core +1 more source
Cardiac Amyloidosis – An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction – Updated Diagnosis and Treatment Options [PDF]
Romanian Journal of Cardiology, 2021 Cardiac amyloidosis (CA) still represents a frequently missed cause of heart failure with preserved ejection fraction (HFpEF). In the light of many new and effective therapies for immunoglobulin light chain amyloidosis (AL) and for transthyretin ...
Roxana Cristina RIMBAS +3 more
doaj +1 more source
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis [PDF]
, 2016 Amyloid light-chain (LC) amyloidosis (AL amyloidosis) is a rare and fatal disease for which there are no approved therapies. In patients with AL amyloidosis, LC aggregates progressively accumulate in organs, resulting in organ failure that is ...
Ando, Y +10 more
core +1 more source
Haematologica, 2014 Examination of abdominal subcutaneous fat aspirates is a practical, sensitive and specific method for the diagnosis of systemic amyloidosis. Here we describe the development and implementation of a clinical assay using mass spectrometry-based proteomics ...
Julie A. Vrana +9 more
doaj +1 more source
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
Hemato, 2021 Non-native immunoglobulin light chain conformations, including aggregates, appear to cause light chain amyloidosis pathology. Despite significant progress in pharmacological eradication of the neoplastic plasma cells that secrete these light chains, in ...
Gareth J. Morgan +2 more
doaj +1 more source
American journal of hematology/oncology, 2020 In localized light chain amyloidosis (locAL), amyloidogenic light chains (aLC) are produced and deposited locally by a B‐cell clone. We present 293 patients with immunohistochemically confirmed locAL.
M. Basset +14 more
semanticscholar +1 more source